Clinical trial
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage…
NCT00117975 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00117975 |
|---|---|
| Title | Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma |
| Official title | A Phase II Trial of Extended Induction Galiximab (Anti-CD80 Monoclonal Antibody) (IND #12373) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL) |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | galiximab, rituximab |
| Enrollment | 62 |
| Start date | Jun 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Aug 1, 2013 |
| First posted | Jul 11, 2005 |
| Last update posted | Jul 6, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: